GLOW: skin repair, vessels and a protein fragment

The blend puts GHK-Cu beside BPC-157 and TB-500. Their research travels through very different tissues before arriving at the same name.

Thymosin beta-4 wound healing

The 1999 thymosin beta-4 wound experiment is strikingly concrete: full-thickness wounds in rats, with new surface coverage measured against saline controls. Re-epithelialization, the rebuilding of the skin's surface, increased by 42% at day 4 and 61% at day 7. Wound contraction, collagen deposition and blood-vessel formation also increased. In cell-migration assays, as little as 10 picograms stimulated migration 2-3-fold.

I appreciate how concretely the experiment describes repair. The material used deserves equal attention: full-length thymosin beta-4. TB-500 is a short fragment of that protein. The broader peptide review discusses the identity and evidence problems around these compounds; reproducing a parent protein's effects with its fragment remains an open question. I give the rat result credit for what it measured, while reserving judgement on the fragment and the blend.

A laboratory rat beside a microscope and a slide on a white work surface — An editorial illustration of the animal and microscopy work behind wound-repair research; an imagined scene.

What it is

GLOW is a non-standardized, supplier- or clinic-formulated combination of three peptides. No universal ratio exists; a commonly cited research-label formulation is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, but ratios and purity vary by source and are unverified outside formal analysis.

Its three constituents each have their own identity:

GHK-Cu is glycyl-L-histidyl-L-lysine chelated 1:1 to a copper(II) ion. Its sequence appears naturally within type I collagen, and it is legal as a topical cosmetic ingredient (Copper Tripeptide-1) under US and EU regulation.
BPC-157 is a stable synthetic pentadecapeptide (fifteen amino acids, sequence GEPPPGKPADDAGLV) derived from a gastric body-protection protein. It has no FDA approval; FDA retains safety concerns alongside its withdrawn compounding nomination.
TB-500 is the acetylated heptapeptide Ac-LKKTETQ, corresponding to the actin-binding region of thymosin beta-4. Most published efficacy data for this fragment use the full-length parent protein instead — a distinction that matters throughout.

Promise Peptides (mypromise.com) prescribes KLOW—a compounded mix in which KPV joins GHK-Cu, BPC-157 and TB-500—only if a licensed U.S. clinician reviews the individual request and decides to prescribe. Some requests are declined; its patient care is confined to the United States, with the choices shaped by a patient's state and the treatment involved. Compounded KLOW has no FDA approval. The existence of that clinical route does not supply the missing GLOW blend-level evidence or turn GLOW into an approved medicine.

BPC-157 in vessels and tendons

BPC-157's contribution begins in another set of models. A 2017 study of vessel-growth signalling used a chick membrane, rat hind-limb ischemia and cultured human vascular endothelial cells. It found increased VEGFR2 expression and activation of the VEGFR2-Akt-eNOS pathway. Angiogenesis means the formation of new blood vessels; here it was investigated through those experimental systems.

The 2003 Achilles-tendon study used Wistar rats with fully transected tendons and also examined rat tendon cells in culture. BPC-157 improved biomechanical and functional recovery and stimulated tendon-cell outgrowth. These are substantial injuries, far removed from an intact skin surface. I think that distance gets lost when every repair result is gathered under a beauty claim.

A 2025 review of BPC-157 found only three small human pilots. No adverse effects were reported in them, but large trials and a validated human safety profile were lacking. The authors treated BPC-157 as investigational.

Combining the ingredients

The rationale for GLOW has a certain appeal: GHK-Cu for matrix remodelling, BPC-157 for vascular signals and TB-500 for cell-migration mechanisms associated with its parent protein. GHK-Cu itself already has a broad remodelling profile, including effects on collagen, elastin and growth-factor signalling across human and animal research. The mechanisms overlap as well as complement one another.

Adding those activities together seems arithmetically tidy; I doubt the biology cooperates. There are no controlled GLOW trials, no established combination pharmacokinetics and no published resolution of the blend's stability and interaction questions. The 2026 review of unapproved peptide therapies identifies scarce rigorous human safety data and the potential for serious harm. It names the constituents; it supplies no trial of this combination.

Community accounts

People describe brighter or smoother-looking skin, softened fine lines, better-looking scars and sometimes reduced hair shedding. Other accounts describe stinging, redness, itching, fatigue, headaches, flushing or a metallic taste. These are anecdotal accounts rather than clinical evidence. The favourable and unfavourable stories both lack the controls needed to identify a blend effect.

Visible changes are compelling. Appearance is what brought many readers to this subject. But a personal account cannot settle which ingredient contributed, what else changed, or how often an adverse effect occurs. Community reports offer questions for a trial; they cannot provide its answers.

GLOW safety and status

GLOW is not FDA-approved. The FDA record for BPC-157, TB-500 and injectable GHK-Cu lists withdrawn compounding nominations with unresolved safety concerns; that withdrawal grants no authority to compound. BPC-157 and TB-500 are WADA-prohibited at all times. The BPC-157 review and the review of peptide therapies in sport discuss the constituent evidence and sporting restrictions. Human safety evidence for full-length thymosin beta-4 includes a Phase 1 study in 40 volunteers; that protein and the TB-500 fragment remain distinct preparations.

The pro-angiogenic mechanisms raise a theoretical cancer concern, because tumours depend on blood vessels. The vascular work on BPC-157 provides a mechanism to investigate, while human studies have yet to establish this risk for GLOW. Copper handling is another concern: the GHK-Cu component carries copper, which matters for conditions such as Wilson's disease. The copper-peptide literature supports attention to that chemistry. Theoretical systemic copper accumulation and unknown long-term combination safety remain unresolved.